Fundz

Maia Biotechnology reported raising $2.44 Million in an initial SEC Form D filing, from an offering of $15.5 Million

PUBLIC · MAIANov 12, 2024$2.4M of $15.5M raised

Amount Raised

$2.44 Million

$2.44 Million sold, per SEC Form D (first sale Oct 28, 2024)

Round Type

Seed

ChicagoBiotechnologyHealth CareScience And EngineeringMedicalTherapeutics

Quick answer

MAIA Biotechnology raised $2.44 Million in a Seed round, dated October 28, 2024. MAIA Biotechnology is based in Chicago, Illinois, United States.

How much did MAIA Biotechnology raise?
MAIA Biotechnology raised $2.44 Million in a Seed round on October 28, 2024.
What does MAIA Biotechnology do?
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend..
Where is MAIA Biotechnology based and how big is it?
MAIA Biotechnology is based in Chicago, Illinois, United States.
Who are the decision-makers at MAIA Biotechnology?
Fundz holds 2 contacts at MAIA Biotechnology, including the Senior Director, Human Resources. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at MAIA Biotechnology, and when

A new round usually means MAIA Biotechnology is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day MAIA Biotechnology raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at MAIA Biotechnology, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at MAIA Biotechnology. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

MAIA Biotechnology

Location

Chicago, Illinois, United States

About

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment MAIA Biotechnology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsSean S., Senior Director, Human ResourcesSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for MAIA Biotechnology's next move

See what Strategic adds

MAIA Biotechnology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.